Corcept Therapeutics

This study tests a drug called relacorilant combined with other treatments for people with ovarian, fallopian tube, peritoneal, or endometrial cancers. About 270 participants will receive the drug combination to see if it slows cancer growth. The goal is to find better options fo…

This study tests a new drug called nenocorilant combined with an immunotherapy (nivolumab) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 50 adults with v…

This early-stage study tests whether the drug miricorilant can lower the amount of fat the liver produces in people with MASH, a serious fatty liver condition. Eight adults with MASH will take the drug for 6 weeks, and researchers will measure changes in liver fat production and …

This study tests whether a new drug called dazucorilant can slow down ALS and improve muscle strength and breathing. About 279 adults with ALS will receive either the drug or a placebo for 24 weeks. The goal is to see if the drug is safe and helps people maintain their daily func…

This study tests whether adding an experimental drug called relacorilant to standard chemotherapy (nab-paclitaxel and gemcitabine) can help people with metastatic pancreatic cancer live longer without their disease getting worse. About 60 adults who have not yet been treated for …